Endoskopická a medikamentózní terapie cévních ektázií žaludečního antra (GAVE): série kazuistik a přehled metod

Stáhnout PDF English version

Autoři: Šramková M.; Kroupa R.; Dastych M.; Konečný Š.; Kunovsky L.; Dolina J.
Působiště autorů: Department of Gastroenterology and Internal Medicine, Universtity Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
Vyšlo v časopise: Gastroent Hepatol 2021; 75(3): 221-228
Kategorie: Rewiev article
doi: https://doi.org/10.48095/ccgh2021221

Souhrn

Cévní ektázie žaludečního antra (GAVE – gastric antral vascular ectasia) je vzácná diagnóza, která může vést ke chronické sideropenické anemii v důsledku okultního nebo zjevného krvácení do gastrointestinálního traktu. Za základ léčby GAVE jsou považovány endoskopické termické metody – z nichž nejužívanější je argon-plazma koagulace, dále radiofrekvenční ablace nebo kryoterapie. Příznivé výsledky jsou publikovány také v souvislosti s používáním endoskopické ligace. V případě GAVE refrakterní na předchozí endoskopickou léčbu lze použít farmakoterapii, jejíž podstatou je redukce tvorby cévních malformací a krevního průtoku v nich. Prezentujeme přehled dostupných endoskopických a neendoskopických metod pro léčbu GAVE a naše zkušenosti s léčbou refrakterní GAVE kombinací endoskopických metod a thalidomidu formou kazuistik. Navrhujeme možný algoritmus pro terapii GAVE.

Klíčová slova:

cévní ektázie žaludečního antra – argon-plazma koagulace – endoskopická ligace – thalidomid – krvácení z trávicího traktu

Zdroje

1. Dulai GS, Jensen DM. Treatment of watermelon stomach. Curr Treat Options Gastroenterol 2006; 9(2): 175–180. doi: 10.1007/ s11938-006-0036-1.

2. Rider JA, Klotz AP, Kirsner JB. Gastritis with veno-capillary ectasia as a source of massive gastric hemorrhage. Gastroenterology 1953; 24(1): 118–123.

3. Gilliam JH 3rd, Geisinger KR, Wu WC et al. Endoscopic biopsy is diagnostic in gastric antral vascular ectasia. The „watermelon stomach“. Dig Dis Sci 1989; 34(6): 885–888. doi: 10.1007/ BF01540274.

4. Gostout CJ, Viggiano TR, Ahlquist DA et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol 1992; 15(3): 256–263. doi: 10.1097/ 000048 36-1992100 00-00019.

5. Kukulska M, Smoła I, Gromny I et al. Watermelon stomach as the first symptom of liver cirrhosis. Gastroenterol Hepatol 2016; 70(5): 422–425. doi: 10.14735/ amgh2016422.

6. Becq A, Rahmi G, Perrod G et al. Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management. Gastrointest Endosc 2017; 86(5): 792–806. doi: 10.1016/ j.gie.2017.05.018.

7. Ward EM, Raimondo M, Rosser BG et al. Prevalence and natural history of gastric antral vascular ectasia in patients undergoing orthotopic liver transplantation. J Clin Gastroenterol 2004; 38(10): 898–900. doi: 10.1097/ 00004836-200411000-00013.

8. Spahr L, Villeneuve JP, Dufresne MP et al. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999; 44(5): 739–742. doi: 10.1136/ gut.44.5.739.

9. Hsu WH, Wang YK, Hsieh MS et al. Insights into the management of gastric antral vascular ectasia (watermelon stomach). Therap Adv Gastroenterol 2018; 11:1756283X17747471. doi: 10.1177/ 1756283X17747471.

10. Naidu H, Huang Q, Mashimo H. Gastric antral vascular ectasia: the evolution of therapeutic modalities. Endosc Int Open 2014; 2(2): E67––E73. doi: 10.1055/ s-0034-1365525.

11. Wells CD, Harrison ME, Gurudu SR et al. Treatment of gastric antral vascular ectasia (watermelon stomach) with endoscopic band ligation. Gastrointest Endosc 2008; 68(2): 231–236. doi: 10.1016/ j.gie.2008.02.021.

12. Swanson E, Mahgoub A, MacDonald R et al. Medical and endoscopic therapies for angiodysplasia and gastric antral vascular ectasia: a systematic review. Clin Gastroenterol Hepatol 2014; 12(4): 571–582. doi: 10.1016/ j.cgh.2013.08.038.

13. Elhendawy M, Mosaad S, Alkhalawany W et al. Randomized controlled study of endoscopic band ligation and argon plasma coagulation in the treatment of gastric antral and fundal vascular ectasia. United European Gastroenterol J 2016; 4(3): 423–428. doi: 10.1177/ 205 0640615619837.

14. Chalhoub JM, Umar J, Groudan K et al. Endoscopic band ligation compared to thermal therapy for gastric antral vascular ectasia: A systematic review and meta-analysis. United European Gastroenterol J 2021; 9(2): 150–158. doi: 10.1177/ 2050640620975243.

15. Magee C, Lipman G, Alzoubaidi D et al. Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia. United European Gastroenterol J 2019; 7(2): 217–224. doi: 10.1177/ 2050640618814659.

16. Mathou NG, Lovat LB, Thorpe SM et al. Nd:YAG laser induces long-term remission in transfusion-dependent patients with watermelon stomach. Lasers Med Sci 2004; 18(4): 213–218. doi: 10.1007/ s10103-003-0284-4.

17. Patel AA, Trindade AJ, Diehl DL et al. Nitrous oxide cryotherapy ablation for refractory gastric antral vascular ectasia. United European Gastroenterol J 2018; 6(8): 1155–1160. doi: 10.1177/ 2050640618783537.

18. Novitsky YW, Kercher KW, Czerniach DR et al. Watermelon stomach: pathophysiology, diagnosis, and management. J Gastrointest Surg 2003; 7(5): 652–661. doi: 10.1016/ s1091-255x(02)00435-3.

19. Junquera F, Feu F, Papo M et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001; 121(5): 1073–1079. doi: 10.1053/ gast.2001.28650.

20. Junquera F, Saperas E, Videla S et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol 2007; 102(2): 254–260. doi: 10.1111/ j.1572-0241.2007.01053.x.

21. Bon C, Aparicio T, Vincent M et al. Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. Aliment Pharmacol Ther 2012; 36(6): 587–593. doi: 10.1111/ apt.12000.

22. McFarlane M, O‘Flynn L, Ventre R et al. Emerging role of thalidomide in the treatment of gastrointestinal bleeding. Frontline Gastroenterol 2018; 9(2): 98–104. doi: 10.1136/ flgastro-2017-100870.

23. Bayudan AM, Chen CH. Thalidomide for refractory gastrointestinal bleeding from vascular malformations in patients with significant comorbidities. World J Clin Cases 2020; 8(15): 3218–3229. doi: 10.12998/ wjcc.v8.i15.3218.

24. Ge ZZ, Chen HM, Gao YJ et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011; 141(5): 1629–1637.e1-4. doi: 10.1053/ j.gastro.2011.07.018.

25. Chen H, Fu S, Feng N et al. Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide. Medicine (Baltimore) 2016; 95(33): e4606. doi: 10.1097/ MD.0000000000004606.

26. Iyer VN, Apala DR, Pannu BS et al. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding. Mayo Clin Proc 2018; 93(2): 155–166. doi: 10.1016/ j.mayocp.2017.11.013.

27. Albitar HAH, Almodallal Y, Gallo De Moraes A et al. Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy. Mayo Clin Proc 2020; 95(8): 1604–1612. doi: 10.1016/ j.mayocp.2020.03.001.

28. Kamath PS, Lacerda M, Ahlquist DA et al. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000; 118(5): 905–911. doi: 10.1016/ s0016-5085(00)70176-4.

29. Barkun AN, Laine L, Leontiadis GI et al. Management of Nonvariceal Upper Gastrointestinal Bleeding. Ann Intern Med 2020; 172(8): 573. doi: 10.7326/ L20-0014.